Current Report Filing (8-k)
January 20 2021 - 3:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): January 20, 2021
INMED PHARMACEUTICALS INC.
(Exact Name of Company as Specified in Charter)
British Columbia
|
|
001-39685
|
|
98-1428279
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
InMed Pharmaceuticals Inc.
Suite 310 - 815 W. Hastings Street,
Vancouver, B.C.
Canada
|
|
V6C 1B4
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Company’s telephone number,
including area code: (604) 669-7207
Not applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Shares, no par value
|
|
INM
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On January 20, 2021, the Company issued a letter
to shareholders, colleagues, and business partners reviewing the Company’s activities in 2020 and certain anticipated activities
in 2021. A copy of the letter is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information set forth in this Item
7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section.
The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and
not filed:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
INMED PHARMACEUTICALS INC.
|
|
|
|
|
Date: January 20, 2021
|
|
|
|
By:
|
|
/s/ Bruce Colwill
|
|
|
|
|
|
|
Bruce Colwill
Chief Financial Officer
|
|
|
|
|
|
|
|
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024